Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.03 USD
Change Today 0.00 / 0.00%
Volume 0.0
ZLDPF On Other Exchanges
Symbol
Exchange
Copenhagen
Berlin
OTC US
OTC US
As of 4:30 PM 03/24/15 All times are local (Market data is delayed by at least 15 minutes).

zealand pharma a/s (ZLDPF) Snapshot

Open
--
Previous Close
$17.03
Day High
--
Day Low
--
52 Week High
03/23/15 - $17.54
52 Week Low
03/2/15 - $12.18
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
23.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZEALAND PHARMA A/S (ZLDPF)

Related News

No related news articles were found.

zealand pharma a/s (ZLDPF) Related Businessweek News

No Related Businessweek News Found

zealand pharma a/s (ZLDPF) Details

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide medicines in Denmark. It offers Lyxumia (Lixisenatide), a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. The company is also developing Lantus (LixiLan), which is in Phase III clinical trials for the treatment of type 2 diabetes; Danegaptide that is in Phase II clinical trials to treat cardiac reperfusion injuries; and Elsiglutide, a GLP-2 receptor agonist, which is in Phase IIb clinical trials for the treatment of chemotherapy-induced diarrhea in patients with colorectal cancer. In addition, it is developing ZP4207 that is in Phase I clinical trials to treat hypoglycemia in diabetes; and ZP2929, a dual acting glucagon/GLP-1 peptide receptor agonist, which is in Phase I clinical trials for the treatment of diabetes and/or obesity. The company has license agreements and partnerships with Sanofi S.A., Helsinn Healthcare S.A., Boehringer Ingelheim International GmbH, and Eli Lilly. Zealand Pharma A/S was founded in 1997 and is based in Copenhagen, Denmark.

103 Employees
Last Reported Date: 03/13/15
Founded in 1997

zealand pharma a/s (ZLDPF) Top Compensated Officers

Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: kr2.1M
Compensation as of Fiscal Year 2014.

zealand pharma a/s (ZLDPF) Key Developments

Zealand Pharma A/S Starts Clinical Development of Multiple-Dose Version of its Stable Glucagon Analogue, ZP4207

Zealand Pharma A/S announced that it has advanced a multiple-dose version of its novel stable glucagon analogue, ZP4207, into clinical development. The ZP4207 multiple-dose version is for the treatment of mild to moderate hypoglycemia in diabetes patients, and could also be an essential component in a dual-hormone artificial pancreas system. ZP4207 is invented and wholly owned by Zealand. The new clinical development program with the multiple- dose version of ZP4207 will run in parallel with Zealand's ongoing clinical development program with ZP4207 as a single-use rescue pen for the treatment of severe hypoglycemia events in diabetes patients on insulin treatment. The new Phase Ib clinical trial initiated with ZP4207 is a randomized, double blind and placebo-controlled study to evaluate primarily the safety and tolerability of the compound after multiple dosing. Secondary endpoints will measure the pharmacokinetics and pharmacodynamics (blood sugar levels) of ZP4207 after multiple dosing. The trial is conducted at a clinical diabetes center in Germany and is planned to enroll 24 healthy volunteers, who will receive three different cohorts of daily doses of ZP4207, each over 5 days. Results from this study is expected in the second half of 2015.

Zealand Pharma Reports Revenue Results for the First Quarter of 2015

Zealand Pharma A/S reported Lyxumia(r) (lixisenatide) royalty revenue of DKK 6.3 /EUR 0.9 million for the first quarter 2015. The reported royalty revenue is based on Sanofi's sales of Lyxumia(r) ex-US in the reported period and represents a 66% increase over the same period in 2014.

Zealand Pharma A/S Announces Management Changes

Zealand Pharma A/S, at the annual general meeting, approved that Daniël Jan Ellens, Chairman and Jørgen Lindegaard, Vice Chairman did not stand for re-election. Catherine Moukheibir, Martin Nichlasson and Rosemary Crane, with Catherine Moukheibir as new Chairman, will comprise the Audit Committee. Martin Nicklasson, Mike J. Owen and Peter Benson, with Martin Niclasson as new Chairman, will comprise the Remuneration and Compensation Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZLDPF:US $17.03 USD 0.00

ZLDPF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZLDPF.
View Industry Companies
 

Industry Analysis

ZLDPF

Industry Average

Valuation ZLDPF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.9x
Price/Book 8.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZEALAND PHARMA A/S, please visit zealandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.